<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>BARBA, LUCIANO Progress Note</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body><h1 class="h1center">BARBA, LUCIANO Progress Note</h1><table class="header_table"><tr><td class="td_header_role_name"><span class="td_label">Patient</span></td><td class="td_header_role_value">LUCIANO BARBA</td></tr><tr><td class="td_header_role_name"><span class="td_label">Date of birth</span></td><td class="td_header_role_value">May 17, 1942 </td></tr><tr><td class="td_header_role_name"><span class="td_label">Current Gender</span></td><td class="td_header_role_value">Male</td></tr><tr><td class="td_header_role_name"><span class="td_label">Race(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>OTHER RACE</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Ethnicity</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>Unknown</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Language(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>Spanish</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Primary Home Address:<br/>4731 AMBER GLEN CT<br/>Las Vegas, NV 89147<br/><br/>Mobile Phone:  (619)559-8015<br/>Email:  lisabarba@gmail.com<br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Patient IDs</span></td><td class="td_header_role_value">326529 2.16.840.1.113883.3.623<br/></td></tr></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document Id</span></td><td class="td_header_role_value">ProgressNote_BARBA_20250430_0934_21.410 2.16.840.1.113883.3.623</td></tr><tr><td class="td_header_role_name"><span class="td_label">Document Created:</span></td><td class="td_header_role_value">April 30, 2025, 09:34:21, MST </td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Jose Valladares of The Oncology Institute of Hope and Innovation</td></tr><tr><td class="td_header_role_value internal_format"><br/><br/><br/></td></tr></tbody></table></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Author</span></td><td class="td_header_role_value">G2Carequality Interface, The Oncology Institute of Hope and Innovation</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value">Arizona, California, Florida<br/>Downey, CA 90241<br/><br/><br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Encounter Id</span></td><td class="td_header_role_value">9937012 2.16.840.1.113883.19</td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Type</span></td><td class="td_header_role_value">OFFICE/OUTPATIENT NEW MODERATE MDM 45 MINUTES</td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Date</span></td><td class="td_header_role_value"> From June 13, 2024  to June 13, 2024 </td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Location</span></td><td class="td_header_role_value"/></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Informant</span></td><td class="td_header_role_value">Jose Valladares of The Oncology Institute of Hope and Innovation</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"><br/><br/><br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document maintained by</span></td><td class="td_header_role_value">McKesson Specialty Health</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value">10101 Woodloch Forest<br/>The Woodlands, TX 77380, USA<br/><br/>Work Phone:  800 381 2637<br/></td></tr></tbody></table><h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Assessment</a></li><li><a href="#id2">Allergies and Adverse Reactions</a></li><li><a href="#id3">Plan</a></li><li><a href="#id4">Reason for Visit</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Immunizations</a></li><li><a href="#id7">Diagnostic Results</a></li><li><a href="#id8">Medications</a></li><li><a href="#id9">Problems</a></li><li><a href="#id10">Vital Signs</a></li><li><a href="#id11">Notes Section</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Assessment</a></h3><div>See Clinical Notes section</div><h3><a name="id2" href="#toc">Allergies and Adverse Reactions</a></h3><div><table>
    <thead>
        <tr>
                            <th>Medication/Group Name</th>
                <th>Reaction</th>
                <th>Severity</th>
                <th>Date</th>
        </tr>
    </thead>
    <tbody>
                <tr ID="AlertOBS-1000">
                    <td colspan="4">No known allergies</td>
                </tr>
    </tbody>
</table>
</div><h3><a name="id3" href="#toc">Plan</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="CarePlanRef-1001">
						<td>07/11/2024</td>
						<td>APPOINTMENT</td>
						<td>PHLEBOTOMY</td>
				</tr>
				<tr ID="CarePlanRef-1002">
						<td>07/11/2024</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1003">
						<td>06/13/2024</td>
						<td>APPOINTMENT</td>
						<td>NEW HEMATOLOGY</td>
				</tr>
				<tr ID="CarePlanRef-1004">
						<td>06/13/2024</td>
						<td>LABORDER</td>
						<td>Ferritin</td>
				</tr>
				<tr ID="CarePlanRef-1005">
						<td>06/13/2024</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
				<tr ID="CarePlanRef-1006">
						<td>06/13/2024</td>
						<td>LABORDER</td>
						<td>Thyroglobulin</td>
				</tr>
				<tr ID="CarePlanRef-1007">
						<td>06/13/2024</td>
						<td>LABORDER</td>
						<td>U/S neck</td>
				</tr>
				<tr ID="CarePlanRef-1008">
						<td>06/13/2024</td>
						<td>LABORDER</td>
						<td>Erythropoietin</td>
				</tr>
				<tr ID="CarePlanRef-1009">
						<td>06/13/2024</td>
						<td>LABORDER</td>
						<td>CMP</td>
				</tr>
				<tr ID="CarePlanRef-1010">
						<td>07/11/2024</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
				<tr ID="CarePlanRef-1011">
						<td>07/11/2024</td>
						<td>LABORDER</td>
						<td>Erythropoietin</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id4" href="#toc">Reason for Visit</a></h3><div>FOLLOW UP</div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="EncounterDiagnosisRef-1012">
							<td>06/13/2024</td>
							<td>Erythrocytosis</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1013">
							<td>06/13/2024</td>
							<td>Polycythemia</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1014">
							<td>06/13/2024</td>
							<td>Primary thyroid cancer</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1015">
							<td>06/13/2024</td>
							<td>Thrombocytopenia, acquired</td>						
					</tr>
	</tbody>
</table>
</div><h3><a name="id6" href="#toc">Immunizations</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Instructions</th>
				<th>Refusal Reason</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
				<tr><td colspan="7">No data for this encounter</td></tr>
	</tbody>
</table>
</div><h3><a name="id7" href="#toc">Diagnostic Results</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Test</th>
				<th>Units</th>
				<th>Lower Limit</th>
				<th>Upper Limit</th>
				<th>Result</th>
				<th>Flag</th>
				<th>Comments</th>
				<th>Status</th>
				<th>Ordered By</th>
				<th>Specimen Source</th>
				<th>Lab Address</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="13">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id8" href="#toc">Medications</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Frequency</th>
				<th>Instructions</th>
				<th>Start Date</th>
				<th>End Date</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="MedicationOBS-1016">
							<td>01/09/2025</td>
							<td>150 ML sodium chloride 9 MG/ML Injection </td>
							<td>intravenously</td>
							<td>500.0 mL</td>
							<td>once</td>
							<td/>
							<td>01/09/2025</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1017">
							<td>12/15/2024</td>
							<td>150 ML sodium chloride 9 MG/ML Injection </td>
							<td>intravenously</td>
							<td>500.0 mL</td>
							<td>once</td>
							<td/>
							<td>12/15/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1018">
							<td>12/05/2024</td>
							<td>dronabinol 5 MG Oral Capsule [Marinol] </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>2 times per day</td>
							<td/>
							<td>12/05/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1019">
							<td>10/10/2024</td>
							<td>Lenvima 24 MG Daily Dose 30 Day Supply Pack </td>
							<td>orally</td>
							<td>14.0 mg</td>
							<td>daily</td>
							<td/>
							<td>10/10/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1020">
							<td>08/29/2024</td>
							<td>Lenvima 24 MG Daily Dose 30 Day Supply Pack </td>
							<td>orally</td>
							<td>14.0 mg</td>
							<td>daily</td>
							<td/>
							<td>08/29/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1021">
							<td>08/28/2024</td>
							<td>Lenvima 24 MG Daily Dose 30 Day Supply Pack </td>
							<td>orally</td>
							<td>14.0 mg</td>
							<td>daily</td>
							<td/>
							<td>08/28/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1022">
							<td>08/22/2024</td>
							<td>{30 (lenvatinib 10 MG Oral Capsule) } Pack </td>
							<td>orally</td>
							<td>10.0 mg</td>
							<td>daily</td>
							<td/>
							<td>08/22/2024</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1023">
							<td>08/20/2024</td>
							<td>{30 (lenvatinib 10 MG Oral Capsule) } Pack </td>
							<td>orally</td>
							<td>10.0 mg</td>
							<td>daily</td>
							<td/>
							<td>08/20/2024</td>
							<td/>
							<td>active</td>
					</tr>
	</tbody>
</table>
</div><h3><a name="id9" href="#toc">Problems</a></h3><div><table>
	<thead>
		<tr>
							<th>Diagnosis</th>
				<th>Status</th>
				<th>Date of Diagnosis</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="ProblemOBS-1024">
						<td>Erythrocytosis</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1025">
						<td>Thrombocytopenia, acquired</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1026">
						<td>Polycythemia</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1027">
						<td>Primary thyroid cancer</td>
						<td>Active</td>
						<td>08/24/2019</td>
				</tr>
				<tr ID="ProblemOBS-1028">
						<td>Hoarseness</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1029">
						<td>Cancer with lung metastasis</td>
						<td>Active</td>
						<td/>
				</tr>
	</tbody>
</table>
</div><h3><a name="id10" href="#toc">Vital Signs</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="VitalSignsRef-1030">
						<td>06/13/2024</td>
						<td>
							Body Temperature
							
						</td>
						<td>96.90</td>
				</tr>
				<tr ID="VitalSignsRef-1031">
						<td>06/13/2024</td>
						<td>
							Heart Beat
							
						</td>
						<td>68.00</td>
				</tr>
				<tr ID="VitalSignsRef-1032">
						<td>06/13/2024</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>16.00</td>
				</tr>
				<tr ID="VitalSignsRef-1033">
						<td>06/13/2024</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>95.00</td>
				</tr>
				<tr ID="VitalSignsRef-1034">
						<td>06/13/2024</td>
						<td>
							BSA
							
						</td>
						<td>1.86</td>
				</tr>
				<tr ID="VitalSignsRef-1035">
						<td>06/13/2024</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1036">
						<td>06/13/2024</td>
						<td>
							Weight
							
						</td>
						<td>168.40</td>
				</tr>
				<tr ID="VitalSignsRef-1037">
						<td>06/13/2024</td>
						<td>
							Height
							
						</td>
						<td>66.00</td>
				</tr>
				<tr ID="VitalSignsRef-1038">
						<td>06/13/2024</td>
						<td>
							BMI
							
						</td>
						<td>27.18</td>
				</tr>
				<tr ID="VitalSignsRef-1039">
						<td>06/13/2024</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>120</td>
				</tr>
				<tr ID="VitalSignsRef-1040">
						<td>06/13/2024</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>75</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id11" href="#toc">Notes Section</a></h3><div>	<ul><li>
		        Follow-Up: 
		        <p>
		        		

<br/>2904 W. Horizon Ridge Pkwy<br/>Suite 200<br/>Henderson , NV  89052

<br/>
<br/>Phone: (702) 471-7779 Fax: (702) 471-0484


<br/>


<br/>Patient Name: LUCIANO BARBA

<br/>Date of Birth: 05/17/1942

<br/>Medical Record #: 326529

<br/>Attending Physician: Yousif, Ammar   

<br/>Location: Henderson 2

<br/>Referring Physician: TRICIA BERNICE MURPHY 

<br/>


<br/>Follow-Up

<br/>Date of Visit: 07/11/2024

<br/>


<br/>History of Present Illness

<br/>Mr. Barba is a nice gentleman of 82 yo who come to our practice(TOI) because a referral of "Thrombocytosis" but after <br/>review the last CBC found erythrocytosis said secondary to OSA Negative for MPL,JAK2, CALR<br/>With History of thyroid Oncocytic malignancy(History of recurrent Follicular carcinoma) s/p total thyroidectomy and iodine <br/>radio ablation<br/>Interim History<br/>07/11/24<br/>Today come for follow up about erythrocytosis didn't do w/u for erythrocytosis but has nodule on on lung concerning<br/>to mets, need additional work up<br/>

<br/>Medical History<br/> <ul><li>Secondary Erythrocytosis</li><li>History of Primary thyroid Oncocytic cancer</li><li>OSA </li><li>History of thyroid Oncocytic malignancy</li><li>History of recurrent Follicular carcinoma</li><li>HTN</li><li>A. Fib</li><li>HPL</li><li>BPH</li><li>Hypothyroidism</li></ul>

<br/>Surgical History<br/> <ul><li>Procedure: Thyroidectomy, NOS</li><li>Procedure: Hernia repair (procedure)</li><li>Hemithyroidectomy then total   </li></ul>

<br/>


<br/>Medications<br/>  Eliquis , Tamsulosin, Finasteride, Diltiazem, Metoprolol, Lisinopril, Levothyroxine  <br/>  

<br/>Smoking History<br/>


<br/>Smoking Tobacco : Never smoker; Smokeless Tobacco : none found; Vaping : none found

<br/>


<br/>Social History

<br/>Alcohol Use: none<br/>Recreational Drug Use: none<br/>children: 4<br/>Marital status: married

<br/>Family History<br/> <ul><li>Father: Deceased</li><li>Mother: Deceased</li><li>Brother 1: Deceased - Brain/CNS cancer, Esophageal cancer</li></ul>

<br/>Allergies<br/> No known medication allergies

<br/>


<br/>Review of Systems<br/>Constitutional: Denies fever, weight loss, fatigue<br/>Eyes: Denies visual changes<br/>ENT/Mouth: Denies hearing problems, oral problems<br/>Cardiovascular: Denies chest pain, palpitations<br/>Respiratory: Denies shortness of breath, cough<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea<br/>Genitourinary: Denies burning, pain on urination, blood in urine, incontinence<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain<br/>Skin: Denies rashes, itchiness, ulcers<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbness<br/>Psychiatric: Denies depression, anxiety<br/>Hematologic/Lymphatic: Denies other bleeding, bruising, swollen lymph nodes

<br/>


<br/>Physical Examination

<br/>Blood pressure: , Pulse: , Temperature: , Respirations: , O2 sat: , Pain Scale: , Height: , <br/>Weight: , BSA: , BMI: 

<br/>General:  Alert &amp; oriented, no acute distress<br/>Skin: Normal<br/>HEENT:  Pupils equal, round. Oral cavity, oropharynx clear<br/>Neck:  Supple, no mass<br/>Breast:  Deferred<br/>Lungs: Clear to auscultation, bilaterally<br/>Heart: Regular rate and rhythm, no murmurs, rubs or gallops<br/>Back: Nontender<br/>Abdomen: Soft, nontender, nondistended, no masses palpable,<br/>no hepatosplenomegaly, normal bowel sounds<br/>Genitourinary: Deferred<br/>Extremities: No clubbing, cyanosis, or edema


<br/>


<br/>Laboratory<br/>
<br/>

<br/>
<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>


<br/>6/7/24<br/>WBC: 5.2, Hb: 17.4,Hct: 51.9 %, Plat: 181 K, EGFR: 61, LFT's: (Normal), TSK 0.76 <br/>



<br/>Radiology<br/>
<br/> PET/CT&amp;/3/19): Findings are highly suspicious for metastatic disease involving bilateral nodes in the neck, left thyroid <br/>lobe nodule, a R pulmonary nodule and possibly in the left super-hilar node in the chest<br/>CT Neck(8/13/19)Enlarged level 2, 4, and 6 cervical chain LN on the R side. Bilateral sub-centimeter cervical chain LN <br/>which are nonspecific by CT but showed increased uptake on PET, suspicious for metastasis. Correlated with <br/>result from PET/CT 7/3/2019. L thyroid lobe nodules. S/p R thyroidectomy.<br/>CT Chest (6/20/24) Pulmonary nodules concerning mets<br/>


<br/>Pathology<br/> <br/>Completion of thyroidectomy(8/24/19) central nodal dissection, and R neck dissection by Dr. Robert Wang. Pathology<br/>showed: L thyroid with multiple follicular adenomas, Oncocytic type, with focus of minimally invasive follicular carcinoma. <br/>No LVI, but positive for ECE, no extra thyroid extension, margins negative. Additional papillary microcarcinoma 0.1cm.<br/>Superior mediastinal LN, 1/2 positive for metastatic follicular carcinoma, 0.8cm, no ECE. Pre-tracheal LN 0/4 negative<br/>L pre-tracheal LN, 1/6 positive, 0.6cm, ECE present. R pre-tracheal LN, 3/4 positive, size of involved lymph node 1.8cm, <br/>ECE present R level 2A LN 1/1 positive, 1.7cm, no ECE. Level 3 anterior LN, 1/1 positive, 1.5cm, no ECE. R level 4 LN, <br/>2/9 positive, 1.6cm, ECE present. R posterior 2A LN, 0/10 negative. R posterior level 3 LN, 1/10 positive, 1.3cm, no ECE<br/>R level 2B LN, 0/11 negative. R-Thyroid resection(4/23/20) Metastatic Oncocytic carcinoma of LN 1/1. No extra-nodal <br/>extension. Final Oncocytic (Hurtle Cell) carcinoma. Confined to thyroid<br/>

<br/>Impression and Recommendations

<br/>1.-Erythrocytosis secondary to OSA  to be done a work up and follow up with the  results for the next approach. Negative<br/>    for MPL,JAK2, CALR, need phlebotomy<br/>2.-History of thyroid Oncocytic malignancy(History of recurrent Follicular carcinoma): Oncocytic carcinoma of the thyroid: <br/>    Historically, Oncocytic carcinoma of the thyroid (previously called Hürthle cell cancer) was considered to be a variant of<br/>    follicular thyroid cancer. However, recent clinical and molecular studies clearly indicate that Oncocytic carcinoma of the <br/>    thyroid is a distinct tumor type. Clinically, Oncocytic carcinoma of the thyroid often has a similar clinical presentation to <br/>    follicular thyroid cancer (usually asymptomatic thyroid nodule in older patients) and a similar pattern of distant metastases <br/>   (lung, bone, brain). Histologically, it is characterized by the presence of a cell population of "oncocytes," mostly eosinophilic<br/>   oxyphilic cells with abundant cytoplasm, closely packed mitochondria and round oval nuclei with prominent nucleoli. Unlike <br/>   follicular thyroid cancer, Oncocytic carcinoma of the thyroid has more of a propensity to spread to cervical lymph nodes. <br/>   While metastatic lesions in follicular thyroid cancer often concentrate radioiodine, Oncocytic carcinoma of the thyroid <br/>   metastatic foci are often radioiodine refractory. Furthermore, the molecular profile of Oncocytic carcinoma of the thyroid is <br/>   very distinct from follicular thyroid cancer. Thus Oncocytic carcinoma of the thyroid is now considered a distinct form of <br/>   follicular cell-derived thyroid cancer<br/>   Per outside note, review at Mayo clinic suggested follicular neoplasm of the R thyroid and R level 3 lymph node. Central <br/>   nodule showed follicular adenoma. Staging imaging (?done post-op) showed hypermetabolic LN in the neck on the R, as <br/>   well as in the upper R paratracheal superior mediastinum, 11x10mm with SUV 7.5, and in or adjacent to the left thyroid bed. <br/>   Small non-specific lung nodules. Has post-op iodine treatment<br/>   CT scan chest has pulmonary nodules concerning mets, needs CT guided Bx<br/>3.-OSA<br/>4.-HTN<br/>5.-A. Fib<br/>6.-HPL<br/>7.-BPH<br/>8.-Hypothyroidism<br/>PLAN<br/>1.-Work up related to erythrocytosis and thyroid cancer and follow up with results<br/>2.- Phlebotomy therapeutic<br/>3.-CT guided Bx<br/>3.-RTC in 4 weeks<br/>
<br/>Discussion<br/>
<br/>ECOG: 0 (Date: 06/13/2024)


<br/>Depression: N/A

<br/>Note: All the questions and concerns were answered to the patient in satisfaction and was giving time ? mins<br/>


<br/>Diagnosis<br/>


<br/>Secondary Erythrocytosis<br/>     

<br/>CC   

<br/>TRICIA BERNICE MURPHY MD
<br/>

<br/>Signature<br/>


<br/>Note created by Jose Valladares MD, Physician, Hematology/Oncology<br/>
<br/>Electronically signed by Jose Valladares MD 07/11/2024 01:20 PM PDT<br/>Reviewed and electronically signed by Ammar Yousif MD 07/11/2024 03:58 PM PDT 
		        </p>
		      </li><li>
		        Initial Consultation: 
		        <p>
		        		

<br/>
<br/>2904 W. Horizon Ridge Pkwy<br/>Suite 200<br/>Henderson , NV  89052

<br/>
<br/>Phone: (702) 471-7779 Fax: (702) 471-0484



<br/>


<br/>Patient Name: LUCIANO BARBA

<br/>Date of Birth: 05/17/1942

<br/>Medical Record #: 326529

<br/>Attending Physician: Ammar Yousif (Hematology/Oncology)  

<br/>Location: Henderson 2

<br/>Referring Physician: TRICIA BERNICE MURPHY MD

<br/>


<br/>Initial Consultation

<br/>Date of Visit: 06/13/2024

<br/>


<br/>Reason for Consultation<br/>
Thrombocytosis

<br/>


<br/>History of Present Illness

<br/>Mr. Barba is a nice gentleman of 82 yo who come to our practice(TOI) because a referral of<br/>"Thrombocytosis" but after review the last CBC found erythrocytosis said secondary to OSA<br/>Negative for MPL,JAK2, CALRWith History of thyroid Oncocytic malignancy(History of recurrent Follicular carcinoma)<br/>s/p total thyroidectomy and iodine radio ablation<br/>

<br/>Medical History<br/>Secondary Erythrocytosis<br/>OSA 

<br/>History of thyroid Oncocytic malignancy<br/>History of recurrent Follicular carcinoma<br/>HTN<br/>A. Fib<br/>HPL<br/>BPH<br/>Hypothyroidism<br/>

<br/>Surgical History<br/> Hemithyroidectomy then total   

<br/>


<br/>Medications<br/> Eliquis , Tamsulosin, Finasteride, Diltiazem, Metoprolol, Lisinopril, Levothyroxine  

<br/>


<br/>Smoking History<br/>


<br/>Smoking Tobacco : Never smoker; Smokeless Tobacco : none found; <br/>Vaping : none found

<br/>


<br/>Social History

<br/>Denied ETOH abuse and illegal drugs<br/>

<br/>Family History<br/> Father: Melanoma<br/>Mother: Stroke   

<br/>


<br/>Allergies<br/> NKDA   

<br/>


<br/>Review of Systems

<br/>Constitutional: Denies fever, weight loss, fatigue<br/>Eyes: Denies visual changes<br/>ENT/Mouth: Denies hearing problems, oral problems<br/>Cardiovascular: Denies chest pain, palpitations<br/>Respiratory: Denies shortness of breath, cough<br/>Gastrointestinal: Denies abdominal pain, nausea, <br/>vomiting, constipation, diarrhea<br/>Genitourinary: Denies burning, pain on urination, <br/>blood in urine, incontinence<br/>Musculoskeletal: Denies muscle pain, bone pain, <br/>joint pain<br/>Skin: Denies rashes, itchiness, ulcers<br/>Neurologic: Denies headaches, dizziness, confusion, <br/>seizures, weakness or numbness<br/>Psychiatric: Denies depression, anxiety<br/>Hematologic/Lymphatic: Denies other bleeding, bruising, <br/>swollen lymph nodes<br/>

<br/>Physical Examination

<br/>Blood pressure: , Pulse: , Temperature: , Respirations: , O2 sat: , <br/>Pain Scale: , Height: , Weight: , BSA: , BMI: 

<br/>General:  Alert &amp; oriented, no acute distress<br/>Skin: Normal<br/>HEENT:  Pupils equal, round. Oral cavity, oropharynx clear<br/>Neck:  Supple, no mass<br/>Breast:  Deferred<br/>Lungs: Clear to auscultation, bilaterally<br/>Heart: Regular rate and rhythm, no murmurs, rubs or gallops<br/>Back: Nontender<br/>Abdomen: Soft, nontender, nondistended, no masses palpable,<br/>no hepatosplenomegaly, normal bowel sounds<br/>Genitourinary: Deferred<br/>Extremities: No clubbing, cyanosis, or edema


<br/>


<br/>Laboratory<br/>
<br/>

<br/>
<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>


<br/>6/7/24<br/>WBC: 5.2, Hb: 17.4,Hct: 51.9 %, Plat: 181 K, EGFR: 61, LFT's: (Normal),<br/>TSK 0.76 <br/>


<br/>Radiology<br/> PET/CT&amp;/3/19): Findings are highly suspicious for metastatic disease involving <br/>bilateral nodes in the neck, left thyroid lobe nodule, a R pulmonary nodule and <br/>possibly in the left super-hilar node in the chest<br/>CT Neck(8/13/19)Enlarged level 2, 4, and 6 cervical chain LN on the R side. <br/>Bilateral sub-centimeter cervical chain LN which are nonspecific by CT but <br/>showed increased uptake on PET, suspicious for metastasis. Correlated with <br/>result from PET/CT 7/3/2019. L thyroid lobe nodules. S/p R thyroidectomy.

<br/>Pathology<br/> <br/>Completion of thyroidectomy(8/24/19) central nodal dissection, and R neck <br/>dissection by Dr. Robert Wang. Pathology showed:<br/>L thyroid with multiple follicular adenomas, Oncocytic type, with focus of minimally<br/>invasive follicular carcinoma. No LVI, but positive for ECE, no extra thyroid extension, <br/>margins negative. Additional papillary microcarcinoma 0.1cm.<br/>Superior mediastinal LN, 1/2 positive for metastatic follicular carcinoma, 0.8cm, no ECE<br/>Pre-tracheal LN 0/4 negative<br/>L pre-tracheal LN, 1/6 positive, 0.6cm, ECE present<br/>R pre-tracheal LN, 3/4 positive, size of involved lymph node 1.8cm, ECE present<br/>R level 2A LN 1/1 positive, 1.7cm, no ECE<br/>Level 3 anterior LN, 1/1 positive, 1.5cm, no ECE<br/>R level 4 LN, 2/9 positive, 1.6cm, ECE present<br/>R posterior 2A LN, 0/10 negative<br/>R posterior level 3 LN, 1/10 positive, 1.3cm, no ECE<br/>R level 2B LN, 0/11 negative<br/>R-Thyroid resection(4/23/20) Metastatic Oncocytic carcinoma of LN 1/1<br/>No extra-nodal extension. Final Oncocytic (Hurtle Cell) carcinoma<br/>Confined to thyroid <br/>

<br/>Impression and Recommendations

<br/>1.-Erythrocytosis secondary to OSA  to be done a work up and follow up with the <br/>    results for the next approach. Negative for MPL,JAK2, CALR<br/>2.-History of thyroid Oncocytic malignancy(History of recurrent Follicular carcinoma):<br/>    Oncocytic carcinoma of the thyroid: Historically, Oncocytic carcinoma of the thyroid <br/>    (previously called Hürthle cell cancer) was considered to be a variant of follicular <br/>    thyroid cancer. However, recent clinical and molecular studies clearly indicate that <br/>   Oncocytic carcinoma of the thyroid is a distinct tumor type. Clinically, Oncocytic <br/>   carcinoma of the thyroid often has a similar clinical presentation to follicular thyroid <br/>   cancer (usually asymptomatic thyroid nodule in older patients) and a similar pattern <br/>   of distant metastases (lung, bone, brain). Histologically, it is characterized by the <br/>   presence of a cell population of "oncocytes," mostly eosinophilic oxyphilic cells with <br/>   abundant cytoplasm, closely packed mitochondria and round oval nuclei with <br/>   prominent nucleoli. Unlike follicular thyroid cancer, Oncocytic carcinoma of the <br/>   thyroid has more of a propensity to spread to cervical lymph nodes. While <br/>   metastatic lesions in follicular thyroid cancer often concentrate radioiodine, <br/>  Oncocytic carcinoma of the thyroid metastatic foci are often radioiodine refractory. <br/>  Furthermore, the molecular profile of Oncocytic carcinoma of the thyroid is very <br/>  distinct from follicular thyroid cancer. Thus Oncocytic carcinoma of the thyroid is now <br/>  considered a distinct form of follicular cell-derived thyroid cancer<br/> Per outside note, review at Mayo clinic suggested follicular neoplasm of the R thyroid <br/> and R level 3 lymph node. Central nodule showed follicular adenoma. Staging imaging <br/> (?done post-op) showed hypermetabolic LN in the neck on the R, as well as in the <br/> upper R paratracheal superior mediastinum, 11x10mm with SUV 7.5, and in or adjacent <br/> to the left thyroid bed. Small non-specific lung nodules. Has post-op iodine treatment<br/>3.-OSA<br/>4.-HTN<br/>5.-A. Fib<br/>6.-HPL<br/>7.-BPH<br/>8.-Hypothyroidism<br/>PLAN<br/>1.-Work up related to erythrocytosis and thyroid cancer and follow up with results<br/>2.- Phlebotomy therapeutic<br/>3.-RTC in 4 weeks<br/>
<br/>Discussion<br/>
<br/>
<br/>ECOG: 0


<br/>Depression: N/A

<br/>Note: All the questions and concerns were answered to the patient in <br/>         satisfaction and was giving time 53 mins<br/>


<br/>Diagnosis<br/>Secondary Erythrocytosis<br/>   

<br/>CC   

<br/>TRICIA BERNICE MURPHY MD<br/>


<br/>Signature<br/>


<br/>Note created by Jose Valladares MD, Physician, Hematology/Oncology<br/>
<br/>Electronically signed by Jose Valladares MD 06/13/2024 01:31 PM PDT<br/>Reviewed and electronically signed by Ammar Yousif MD 06/14/2024 03:31 PM PDT 
		        </p>
		      </li></ul>
</div><br/><br/></body></html>